Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan

• Status: Completed
• Trial end date: 1995-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Collaborators: European Union; United Nations High Commissioner for Refugees; World Health Organization
• Treatments: Chloroquine; Chloroquine diphosphate

Criteria

Inclusion Criteria:

• slide-confirmed infection with P. falciparum only

• initial parasite density of 1000-100,000 asexual parasites/μl

• absence of severe malnutrition

• ability to attend stipulated follow-up visits and easy access to facility

• informed consent provided by patient or parent/guardian

• absence of history of hypersensitivity reactions to CQ

Exclusion Criteria:

• infants under six months old

• pregnancy or lactation

• underlying chronic severe illness

• patients with other febrile illnesses

• parasitaemia outside the range of 1000-100,000 asexual parasites/µl

• severe malaria